Rigel Pharmaceuticals | RIGL - Le Chiffre D'Affaires De Vente





Ventes Changement Date
Agenus USD 34.2M 3.97M 2025-12
Amgen USD 9.9B 340M 2025-12
Anika Therapeutics USD 30.62M 2.8M 2025-12
Arrowhead Research USD 264.03M 7.56M 2025-12
AstraZeneca USD 15.5B 313M 2025-12
BioMarin Pharmaceutical USD 875M 99M 2025-12
Bristol-Myers Squibb USD 12.5B 300M 2025-12
Celldex Therapeutics USD 121K 769K 2025-12
Daiichi Sankyo JPY 558.11B 57.35B 2025-12
Eli Lilly USD 19.3B 1.7B 2025-12
Halozyme Therapeutics USD 451.76M 97.76M 2025-12
Heron Therapeutics USD 40.59M 2.38M 2025-12
Intrexon USD 717K 511K 2024-06
Ionis Pharmaceuticals USD 203M 46M 2025-12
Karyopharm Therapeutics USD 30.54M 8.24M 2024-12
Ligand Pharmaceuticals USD 59.66M 55.8M 2025-12
MacroGenics USD 41.23M 31.61M 2025-12
Neurocrine Biosciences USD 805.5M 10.6M 2025-12
Pfizer USD 17.58B 880M 2025-12
Regeneron Pharmaceuticals USD 3.88B 130M 2025-12
Rigel Pharmaceuticals USD 55.31M 18.47M 2024-09
Sangamo BioSciences USD 356K 125K 2024-06
Ultragenyx Pharmaceutical USD 207M 47M 2025-12
Veracyte USD 140.6M 8.7M 2025-12